Señales en vivo de TCRR | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 may 2023 @ 16:00):

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer...

Stats
Volumen de hoy	3.75M
Volumen promedio	325 040
Capitalización de mercado	58.11M
EPS	$0 ( 2024-03-21 )
Próxima fecha de ganancias	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.352
ATR14	$0.105 (7.09%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-01	Tang Kevin C	Sell	4 394 800	Common Stock
2023-06-01	Ubs Oncology Impact Fund L.p.	Sell	3 370 982	Common Stock
2023-06-01	Mpm Sunstates Fund, L.p.	Sell	4 158 964	Common Stock
2023-06-01	Mpm Bioventures 2014, L.p.	Sell	4 158 964	Common Stock
2023-06-01	Gadicke Ansbert	Sell	3 370 982	Common Stock

INSIDER POWER
-89.66
Last 99 transactions
Buy: 1 629 400 \| Sell: 23 030 678

Volumen Correlación

Largo: 0.06 (neutral)

Corto: -0.70 (moderate negative)

Signal:(27.338) Neutral

TCR2 Therapeutics Inc Correlación

10 Correlaciones Más Positivas
ROAD	0.928
STLD	0.926
RAIL	0.918
HEES	0.911
EQRR	0.906
FTXN	0.903
DXPE	0.9
PIE	0.896
THRN	0.895
ATOS	0.895

10 Correlaciones Más Negativas
BOCH	-0.936
BNIXU	-0.929
RGC	-0.919
ISPC	-0.897
MMAC	-0.891
ACXP	-0.885
HCDIP	-0.883
TSP	-0.876
NETE	-0.87
ORPH	-0.867

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TCR2 Therapeutics Inc Correlación - Moneda/Commodity

0.76
( moderate )

0.19
( neutral )

0.00
( neutral )

0.44
( neutral )

-0.77
( moderate negative )

TCR2 Therapeutics Inc Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-3.93

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-3.93

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-3.57

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.40

Financial Reports:

No articles found.

TCR2 Therapeutics Inc

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Actualizaciones en tiempo real para TCR2 Therapeutics Inc [TCRR]

Upcoming Earnings Alert